ARDANA SIGNS AGREEMENT WITH TWINPHARMA

TO MARKET STRIANT™SR

IN THE NETHERLANDS

Edinburgh, UK, 13 February 2007:  Ardana plc (LSE:ARA) today announces that it has signed an agreement granting TwinPharma BV (“TwinPharma”) exclusive rights to market Striant™ SR in the Netherlands.

Striant™ SR is a mucoadhesive buccal (gum surface) testosterone replacement therapy for confirmed male hypogonadism (i.e. those suffering from a deficiency or absence of testosterone). Striant™ SR is the first-to-market buccal adhesive tablet and is marketed to urologists and endocrinologists by Ardana’s own sales force in the UK, and via partners in Germany, Ireland and the Nordic Region.

TwinPharma will shortly launch Striant™ SR in the Netherlands as pricing and reimbursement has now been agreed with the Netherlands Health Authority.

Dr. Maureen Lindsay, Chief Executive of Ardana, said: “Today’s announcement shows Ardana’s continued commitment to expand its product portfolio into the European market with specialist collaborations in each country.  We are very pleased to be working with TwinPharma to ensure that we continue to introduce novel therapies for indications where there are unmet patient needs.”

Gert van Alewijk and Bauke Buwalda, founders of TwinPharma, said:  “We set up TwinPharma with the ambition to introduce novel medicines into the Dutch market. Striant™ SR is a truly novel therapy and fits perfectly with the strategic view of TwinPharma. The collaboration with Ardana Bioscience is very professional and inspiring and we are looking forward to a successful and pleasant cooperation.”

For more information contact:

About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, a $25.5 billion market.

Since its foundation, Ardana has built a broad and balanced portfolio to manage risk and actively pursues product and technology in-licensing and outlicensing to maintain a robust pipeline.

Ardana’s lead products are summarised below:

• Emselex®, a once a day treatment for the symptoms of overactive bladder syndrome, which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited;
• Striant™ SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism;
• Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis);
• Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials;
• Invicorp™, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe and has been launched in Denmark.
• EP01572 a growth hormone secretagogue in late stage development for the diagnosis of growth hormone deficiency 

In addition, Ardana has a strong portfolio of follow-on products in development.  Ardana is listed on the Main Market of the London Stock Exchange.

For further information please see www.ardana.co.uk

back to top